Advertisement

Fractionated Radiosurgery

  • Giuseppe Minniti
  • Claudia Scaringi
Chapter

Abstract

Fractionated stereotactic radiosurgery (SRS) is emerging as an effective treatment option for relatively large intracranial tumors, with the aim of improving the balance between tumor control and normal tissue toxicity over single-fraction SRS, particularly for large lesions or lesions located in critical areas of the brain. Several published studies have reported excellent clinical outcomes and acceptable toxicity after fractionated SRS for primary and secondary brain tumors delivered with different machines, including the Gamma Knife, the CyberKnife, or a modified linear accelerator (LINAC). Current published data support the use of fractionated SRS for relatively large tumors or tumors in close proximity to critical anatomic structures, such as the optic apparatus or the brainstem, that are generally not suitable for SRS; however, future clinical and biologic research is needed to definitively establish the advantages of fractionated SRS over other radiation techniques and the optimal radiation dose and fractionation according to the different brain tumors. A critical analysis of the fundamental radiobiological principles, clinical results, and toxicity of fractionated SRS for brain tumors is presented with an attempt of defining the advantages and limits of the technique.

Keywords

Stereotactic radiosurgery Hypofractionated radiotherapy Meningiomas Pituitary adenomas Acoustic schwannomas Brain metastases Gliomas 

References

  1. 1.
    Leksell L. Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry. 1983;46:797–803.CrossRefGoogle Scholar
  2. 2.
    Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291–8.CrossRefGoogle Scholar
  3. 3.
    Kirkpatrick JP, Soltys SG, Lo SS, Beal K, Shrieve DC, Brown PD. The radiosurgery fractionation quandary: single fraction or hypofractionation? Neuro-Oncology. 2017;19:ii38–49.CrossRefGoogle Scholar
  4. 4.
    Chang SD, Adler JR Jr. Current status and optimal use of radiosurgery. Oncology (Williston Park). 2001;15:209–16; discussion 219–21Google Scholar
  5. 5.
    Shrieve DC. Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors. Neurosurg Clin N Am. 2006;17:67–78.CrossRefGoogle Scholar
  6. 6.
    Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679–94.CrossRefGoogle Scholar
  7. 7.
    Song CW, Cho LC, Yuan J, Dusenbery KE, Griffin RJ, Levitt SH. Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model. Int J Radiat Oncol Biol Phys. 2013;87:18–9.CrossRefGoogle Scholar
  8. 8.
    Williams MV, Denekamp J, Fowler JF. A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys. 1985;11:87–96.CrossRefGoogle Scholar
  9. 9.
    Hall EJ, Brenner DJ. The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys. 1993;25:381–5.CrossRefGoogle Scholar
  10. 10.
    Santacroce A, Kamp MA, Budach W, Hänggi D. Radiobiology of radiosurgery for the central nervous system. Biomed Res Int. 2013;2013:362761.CrossRefGoogle Scholar
  11. 11.
    Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83:554–68.CrossRefGoogle Scholar
  12. 12.
    Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008;18:240–3.CrossRefGoogle Scholar
  13. 13.
    Joiner M. Quantifying cell kill and survival. In: Joiner M, Van der Kogel A, editors. Basic clinical radiobiology. 4th ed. London: Hodder Arnold; 2009. p. 102–19.CrossRefGoogle Scholar
  14. 14.
    Minniti G, Scaringi C, Clarke E, Valeriani M, Osti M, Enrici RM. Frameless linac-based stereotactic radiosurgery (SRS) for brain metastases: analysis of patient repositioning using a mask fixation system and clinical outcomes. Radiat Oncol. 2011;6:158.CrossRefGoogle Scholar
  15. 15.
    Rahimian J, Chen JC, Rao AA, Girvigian MR, Miller MJ, Greathouse HE. Geometrical accuracy of the Novalis stereotactic radiosurgery system for trigeminal neuralgia. J Neurosurg. 2004;101(Suppl 3):351–5.CrossRefGoogle Scholar
  16. 16.
    Wurm RE, Erbel S, Schwenkert I, Gum F, Agaoglu D, Schild R, et al. Novalis frameless image-guided noninvasive radiosurgery: initial experience. Neurosurgery. 2008;62(Suppl):A11–7.CrossRefGoogle Scholar
  17. 17.
    Lamba M, Breneman JC, Warnick RE. Evaluation of image-guided positioning for frameless intracranial radiosurgery. Int J Radiat Oncol Biol Phys. 2009;74:913–9.CrossRefGoogle Scholar
  18. 18.
    Ramakrishna N, Rosca F, Friesen S, Tezcanli E, Zygmanszki P, Hacker F. A clinical comparison of patient setup and intra-fraction motion using frame based radiosurgery versus a frameless image-guided radiosurgery system for intracranial lesions. Radiother Oncol. 2010;95:109–15.CrossRefGoogle Scholar
  19. 19.
    Gevaert T, Verellen D, Tournel K, Linthout N, Bral S, Engels B, et al. Setup accuracy of the Novalis ExacTrac 6DOF system for frameless radiosurgery. Int J Radiat Oncol Biol Phys. 2012;82:1627–35.CrossRefGoogle Scholar
  20. 20.
    Clark BG, Souhami L, Pla C, Al-Amro AS, Bahary JP, Villemure JG, et al. The integral biologically effective dose to predict brain stem toxicity of hypofractionated stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1998;40:667–75.CrossRefGoogle Scholar
  21. 21.
    Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18:215–22.CrossRefGoogle Scholar
  22. 22.
    Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S42–9.CrossRefGoogle Scholar
  23. 23.
    Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.CrossRefGoogle Scholar
  24. 24.
    Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S28–35.CrossRefGoogle Scholar
  25. 25.
    Kirkpatrick JP, Marks LB, Mayo CS, Lawrence YR, Bhandare N, Ryu S. Estimating normal tissue toxicity in radiosurgery of the CNS: application and limitations of QUANTEC. J Radiosurg SBRT. 2011;1:95–107.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Minniti G, Esposito V, Clarke E, Scaringi C, Bozzao A, Falco T, et al. Fractionated stereotactic radiosurgery for patients with skull base metastases from systemic cancer involving the anterior visual pathway. Radiat Oncol. 2014;9:110.CrossRefGoogle Scholar
  27. 27.
    Hiniker SM, Modlin LA, Choi CY, Atalar B, Seiger K, Binkley MS, et al. Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery. Semin Radiat Oncol. 2016;26:97–104.CrossRefGoogle Scholar
  28. 28.
    Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F, et al. Single-Fraction Versus Multifraction (3 × 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. Int J Radiat Oncol Biol Phys. 2016;95:1142–8.CrossRefGoogle Scholar
  29. 29.
    Minniti G, D’Angelillo RM, Scaringi C, Trodella LE, Clarke E, Matteucci P, et al. Fractionated stereotactic radiosurgery for patients with brain metastases. J Neuro-Oncol. 2014;117:295–301.CrossRefGoogle Scholar
  30. 30.
    Aoyama H, Shirato H, Onimaru R, Kagei K, Ikeda J, Ishii N, et al. Hypofractionated stereotactic radiotherapy alone without whole brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys. 2003;56:793–800.CrossRefGoogle Scholar
  31. 31.
    Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. Radiother Oncol. 2006;8:18–24.CrossRefGoogle Scholar
  32. 32.
    Murai T, Ogino H, Manabe Y, Iwabuchi M, Okumura T, Matsushita Y, et al. Fractionated stereotactic radiotherapy using CyberKnife for the treatment of large brain metastases: a dose escalation study. Clin Oncol (R Coll Radiol). 2014;26:151–8.CrossRefGoogle Scholar
  33. 33.
    Kim JW, Park HR, Lee JM, Kim JW, Chung HT, Kim DG, et al. Fractionated stereotactic gamma knife radiosurgery for large brain metastases: a retrospective, single center study. PLoS One. 2016;11:e0163304.CrossRefGoogle Scholar
  34. 34.
    Minniti G, Esposito V, Clarke E, Scaringi C, Lanzetta G, Salvati M, et al. Multidose stereotactic radiosurgery (9 Gy × 3) of the postoperative resection cavity for treatment of large brain metastases. Int J Radiat Oncol Biol Phys. 2013;86:623–9.CrossRefGoogle Scholar
  35. 35.
    Ahmed KA, Freilich JM, Abuodeh Y, Figura N, Patel N, Sarangkasiri S, et al. Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases. J Neuro-Oncol. 2014;118:179–86.CrossRefGoogle Scholar
  36. 36.
    Ling DC, Vargo JA, Wegner RE, Flickinger JC, Burton SA, Engh J, et al. Postoperative stereotactic radiosurgery to the resection cavity for large brain metastases: clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection. Neurosurgery. 2015;76:150–6; discussion 156–7.CrossRefGoogle Scholar
  37. 37.
    Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75:156–63.CrossRefGoogle Scholar
  38. 38.
    McKenzie JT, Guarnaschelli JN, Vagal AS, Warnick RE, Breneman JC. Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas. J Neuro-Oncol. 2013;113:403–9.CrossRefGoogle Scholar
  39. 39.
    Minniti G, Scaringi C, De Sanctis V, Lanzetta G, Falco T, Di Stefano D, et al. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas. J Neuro-Oncol. 2013;111:187–94.CrossRefGoogle Scholar
  40. 40.
    Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P. Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients. Neurosurgery. 2009;64(2 Suppl):A7–13.CrossRefGoogle Scholar
  41. 41.
    Bria C, Wegner RE, Clump DA, Vargo JA, Mintz AH, Heron DE, et al. Fractionated stereotactic radiosurgery for the treatment of meningiomas. J Cancer Res Ther. 2011;7:52–7.CrossRefGoogle Scholar
  42. 42.
    Iwata H, Sato K, Tatewaki K, Yokota N, Inoue M, Baba Y, et al. Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro-Oncology. 2011;13:916–22.CrossRefGoogle Scholar
  43. 43.
    Hansasuta A, Choi CYH, Gibbs IC. Multisession stereotactic radiosurgery for vestibular schwannomas: single-institution experience with 383 cases. Neurosurgery. 2011;69:1200–9.CrossRefGoogle Scholar
  44. 44.
    Patel MA, Marciscano AE, Hu C, Jusué-Torres I, Garg R, Rashid A, et al. Long-term treatment response and patient outcomes for vestibular Schwannoma patients treated with hypofractionated stereotactic radiotherapy. Front Oncol. 2017;7:200.CrossRefGoogle Scholar
  45. 45.
    Fahrig A, Ganslandt O, Lambrecht U, Grabenbauer G, Kleinert G, Sauer R, et al. Hypofractionated stereotactic radiotherapy for brain metastases--results from three different dose concepts. Strahlenther Onkol. 2007;183:625–30.CrossRefGoogle Scholar
  46. 46.
    Narayana A, Chang J, Yenice K, Chan K, Lymberis S, Brennan C, et al. Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases. Stereotact Funct Neurosurg. 2007;85:82–7.CrossRefGoogle Scholar
  47. 47.
    Wegner RE, Leeman JE, Kabolizadeh P, Rwigema JC, Mintz AH, Burton SA, et al. Fractionated stereotactic radiosurgery for large brain metastases. Am J Clin Oncol. 2015;38:135–9.CrossRefGoogle Scholar
  48. 48.
    Eaton BR, LaRiviere MJ, Kim S, Prabhu RS, Patel K, Kandula S, et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neuro-Oncol. 2015;123:103–11.CrossRefGoogle Scholar
  49. 49.
    Wang CC, Floyd SR, Chang CH, Warnke PC, Chio CC, Kasper EM, et al. Cyberknife hypofractionated stereotactic radiosurgery (HSRS) of resection cavity after excision of large cerebral metastasis: efficacy and safety of an 800 cGy × 3 daily fractions regimen. J Neuro-Oncol. 2012;106:601–10.CrossRefGoogle Scholar
  50. 50.
    Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, et al. Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. J Neuro-Oncol. 2015;122:559–66.CrossRefGoogle Scholar
  51. 51.
    Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, et al. Multicenter, phase 1, dose escalation study of hypofractionated stereotactic radiation therapy with bevacizumab for recurrent glioblastoma and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 2017;99:797–804.CrossRefGoogle Scholar
  52. 52.
    Minniti G, Amichetti M, Enrici RM. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol. 2009;4:42.CrossRefGoogle Scholar
  53. 53.
    Régis J, Carron R, Delsanti C, Porcheron D, Thomassin JM, Murracciole X, et al. Radiosurgery for vestibular schwannomas. Neurosurg Clin N Am. 2013;24:521–30.CrossRefGoogle Scholar
  54. 54.
    Minniti G, Osti MF, Niyazi M. Target delineation and optimal radiosurgical dose for pituitary tumors. Radiat Oncol. 2016;11:135.CrossRefGoogle Scholar
  55. 55.
    Navarria P, Pessina F, Cozzi L, Clerici E, Villa E, Ascolese AM, et al. Hypofractionated stereotactic radiation therapy in skull base meningiomas. J Neuro-Oncol. 2015;124:283–9.CrossRefGoogle Scholar
  56. 56.
    Adler JR Jr, Gibbs IC, Puataweepong P, Chang SD. Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions. Neurosurgery. 2008;62(Suppl 2):733–43.PubMedGoogle Scholar
  57. 57.
    Tuniz F, Soltys SG, Choi CY, Chang SD, Gibbs IC, Fischbein NJ, et al. Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study. Neurosurgery. 2009;65:898–907.CrossRefGoogle Scholar
  58. 58.
    Han J, Girvigian MR, Chen JC, Miller MJ, Lodin K, Rahimian J, et al. A comparative study of stereotactic radiosurgery, hypofractionated, and fractionated stereotactic radiotherapy in the treatment of skull base meningioma. Am J Clin Oncol. 2014;37:255–60.CrossRefGoogle Scholar
  59. 59.
    Killory BD, Kresl JJ, Wait SD, Ponce FA, Porter R, White WL. Hypofractionated CyberKnife radiosurgery for perichiasmatic pituitary adenomas: early results. Neurosurgery. 2009;64(2 Suppl):A19–25.CrossRefGoogle Scholar
  60. 60.
    Liao HI, Wang CC, Wei KC, Chang CN, Hsu YH, Lee ST, et al. Fractionated stereotactic radiosurgery using the Novalis system for the management of pituitary adenomas close to the optic apparatus. J Clin Neurosci. 2014;21:111–5.CrossRefGoogle Scholar
  61. 61.
    Iwata H, Sato K, Nomura R, Tabei Y, Suzuki I, Yokota N, et al. Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus. J Neuro-Oncol. 2016;128:267–75.CrossRefGoogle Scholar
  62. 62.
    Kapoor S, Batra S, Carson K, Shuck J, Kharkar S, Gandhi R, et al. Long-term outcomes of vestibular schwannomas treated with fractionated stereotactic radiotherapy: an institutional experience. Int J Radiat Oncol Biol Phys. 2011;81:647–53.CrossRefGoogle Scholar
  63. 63.
    Tsai JT, Lin JW, Lin CM. Clinical evaluation of cyberknife in the treatment of vestibular schwannomas. Biomed Res Int. 2013;2013:297093.CrossRefGoogle Scholar
  64. 64.
    Vivas EX, Wegner R, Conley G. Treatment outcomes in patients treated with CyberKnife radiosurgery for vestibular schwannoma. Otol Neurotol. 2014;35:162–70.CrossRefGoogle Scholar
  65. 65.
    Rudà R, Franchino F, Soffietti R. Treatment of brain metastasis: current status and future directions. Curr Opin Oncol. 2016;28:502–10.CrossRefGoogle Scholar
  66. 66.
    Trino E, Mantovani C, Badellino S, Ricardi U, Filippi AR. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. Expert Rev Anticancer Ther. 2017;17:347–56.CrossRefGoogle Scholar
  67. 67.
    Di Lorenzo R, Ahluwalia MS. Targeted therapy of brain metastases: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9:781–96.CrossRefGoogle Scholar
  68. 68.
    Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015;1:1325–32.CrossRefGoogle Scholar
  69. 69.
    Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379–88.CrossRefGoogle Scholar
  70. 70.
    Habets TH, Oth T, Houben AW, Huijskens MJ, Senden-Gijsbers BL, Schnijderberg MC, et al. Fractionated radiotherapy with 3 × 8 Gy induces systemic anti-tumour responses and abscopal tumour inhibition without modulating the humoral anti-tumour response. PLoS One. 2016;11:e0159515.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Giuseppe Minniti
    • 1
    • 2
  • Claudia Scaringi
    • 1
    • 3
  1. 1.Radiation Oncology Unit, UPMC Hillman Cancer Center, San Pietro HospitalRomeItaly
  2. 2.IRCSS NeuromedPozzilliItaly
  3. 3.Radiation Oncology UnitSant’Andrea Hospital, University SapienzaRomeItaly

Personalised recommendations